Maple SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide that has emerged as one of the most studied compounds in mitochondrial medicine research. Unlike conventional antioxidants that struggle to penetrate cellular membranes, SS-31 concentrates within mitochondria at concentrations over 1,000-fold higher than extracellular levels, selectively binding cardiolipin on the inner mitochondrial membrane. This unique pharmacological profile has generated substantial preclinical and clinical data across cardiovascular, neurodegenerative, and metabolic research models. For Canadian researchers investigating mitochondrial dysfunction, SS-31 represents a structurally distinct approach to organelle-targeted intervention.
For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.
Molecular Structure and Mitochondrial Targeting Mechanism
SS-31 is a synthetic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2 (where Dmt is 2′,6′-dimethyltyrosine). Its molecular weight is approximately 640 Da, and its alternating aromatic-cationic motif is critical to its mechanism. The two positive charges (from arginine and lysine residues) drive electrostatic attraction to the negatively charged cardiolipin molecules embedded in the inner mitochondrial membrane.
A 2020 study published in Proceedings of the National Academy of Sciences (PNAS) mapped the mitochondrial protein interaction landscape of SS-31, identifying that the peptide interacts with multiple components of the electron transport chain, including complexes I, III, and IV, as well as the ATP synthase complex (Chavez et al., 2020, PNAS 117(26):15363-15373). This interaction stabilizes the cristae structure where oxidative phosphorylation occurs, directly supporting efficient ATP generation.
Cardiolipin constitutes approximately 15-20% of the total lipid content of the inner mitochondrial membrane and is essential for the structural integrity of respiratory supercomplexes. Research published in the Journal of Biological Chemistry demonstrated that SS-31 binds lipid bilayers containing cardiolipin and modulates surface electrostatics, reducing the tendency of cardiolipin to undergo peroxidation under oxidative stress conditions (Birk et al., 2013). This is significant because cardiolipin peroxidation is a recognized upstream trigger of mitochondrial dysfunction in aging and disease models.
Preclinical Evidence: Cardiac Function in Aging Models
Some of the most compelling preclinical data for SS-31 comes from aging research. A 2020 study published in eLife demonstrated that 8 weeks of SS-31 treatment (3 mg/kg/day) in aged mice (24 months old) substantially reversed cardiac diastolic dysfunction. Treated animals showed normalized proton leak, reduced mitochondrial reactive oxygen species (ROS) production in cardiomyocytes, and increased mitochondrial membrane potential consistent with restored electron transport chain efficiency (Chiao et al., 2020, eLife 9:e55513).
The same research group reported that SS-31 treatment reversed age-related changes in the cardiac proteome, restoring the expression profile of over 900 proteins toward patterns observed in young (5-month-old) hearts. This included normalization of proteins involved in fatty acid oxidation, a pathway that declines significantly with cardiac aging and contributes to the metabolic inflexibility observed in aged hearts.
In a separate preclinical model, SS-31 administration improved ADP sensitivity in aged mitochondria by increasing uptake through the adenine nucleotide translocator (ANT), as reported in a 2023 study (Pharaoh et al., 2023). This finding is significant because reduced ADP transport efficiency is a hallmark of mitochondrial aging that directly limits ATP synthesis capacity even when electron transport chain components remain functional.
Barth Syndrome Clinical Trial Data
The most advanced clinical data for SS-31/elamipretide comes from studies in Barth syndrome, a rare X-linked genetic disorder caused by mutations in the tafazzin gene that impair cardiolipin remodeling. The TAZPOWER trial was a phase 2/3 randomized clinical trial (n=12) followed by an open-label extension, published in Genetics in Medicine (Thompson et al., 2021).
Key findings from the trial:
- At week 12 of the open-label extension (n=10), six-minute walk test (6MWT) distance improved by a mean of 60.5 meters from baseline, representing a 16% increase (paired t-test: p=0.02)
- At week 36 (n=8), 6MWT improvement reached 95.9 meters, a 25% increase from baseline (paired t-test: p=0.02)
- Hand-held dynamometry showed mean muscle strength improvement of 37.9 newtons (30% increase, p=0.003) at week 12, increasing to 56.0 newtons (42% improvement, p=0.001) at week 36
- Cardiac stroke volume improvements were observed in treated subjects over the extension period
Long-term extension data spanning 168 weeks, published in Genetics in Medicine (2024), confirmed durability of these functional improvements. These results contributed to the FDA’s accelerated approval of elamipretide (branded as Forzinity) for Barth syndrome in September 2025.
Ischemia-Reperfusion Injury Research
SS-31 has been extensively studied in models of ischemia-reperfusion (I/R) injury, where temporary blood flow interruption followed by restoration causes paradoxical tissue damage through mitochondrial ROS generation. Preclinical data in renal I/R models demonstrated that SS-31 administration preserved mitochondrial cristae structure, reduced tubular cell apoptosis, and attenuated acute kidney injury severity when administered prior to ischemic insult.
In cardiac I/R models, SS-31 reduced infarct size and preserved left ventricular function in multiple independent studies. The mechanism involves prevention of cardiolipin peroxidation during the reperfusion phase, which otherwise triggers cytochrome c release and activates apoptotic cascades. This positions SS-31 as a research tool for studying the role of mitochondrial membrane lipid integrity in post-ischemic tissue damage.
Neurodegenerative Disease Research Models
Mitochondrial dysfunction is increasingly recognized as a feature of neurodegenerative conditions, and SS-31 has been investigated in several relevant preclinical models. A comprehensive 2025 review published in the International Journal of Molecular Sciences (Russo et al., 2025, IJMS 26(3):944) catalogued evidence across Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis models, noting that SS-31 consistently reduced oxidative damage markers and preserved mitochondrial membrane potential in neuronal cell cultures exposed to neurotoxic insults.
In aged mouse models, SS-31 treatment improved synaptic mitochondrial function and reduced age-related cognitive decline as measured by behavioral testing. These findings are consistent with the hypothesis that neuronal mitochondrial dysfunction drives synaptic failure before overt neurodegeneration occurs.
Key Research Findings
- SS-31 concentrates in mitochondria at >1,000x extracellular levels through electrostatic binding to cardiolipin (15-20% of inner membrane lipid)
- Interacts with electron transport chain complexes I, III, IV, and ATP synthase, stabilizing respiratory supercomplexes (Chavez et al., 2020, PNAS)
- 8-week treatment reversed cardiac diastolic dysfunction in 24-month-old mice, normalizing proton leak and ROS production (Chiao et al., 2020, eLife)
- TAZPOWER trial: 95.9 m improvement in 6MWT (25%, p=0.02) and 56.0 N muscle strength gain (42%, p=0.001) at 36 weeks in Barth syndrome subjects
- Received FDA accelerated approval for Barth syndrome (September 2025) as Forzinity
- Preclinical efficacy demonstrated in cardiac, renal, and neurological I/R injury models through cardiolipin stabilization
- Improves ADP transport through adenine nucleotide translocator in aged mitochondria (Pharaoh et al., 2023)
Structural and Stability Considerations for Research Use
SS-31 is typically supplied as a lyophilized powder with purity verified by HPLC analysis. The peptide is soluble in aqueous buffers at physiological pH due to its net positive charge. For research applications, reconstitution in sterile water or phosphate-buffered saline is standard practice. Once reconstituted, aliquoting and storage at -20°C is recommended to prevent freeze-thaw degradation cycles.
The inclusion of the non-natural amino acid Dmt (2′,6′-dimethyltyrosine) contributes to enhanced metabolic stability compared to peptides composed entirely of natural amino acids, as the dimethyl substitutions provide steric protection against enzymatic degradation. Researchers should verify peptide identity and purity through independent certificate of analysis (COA) documentation before use in experimental protocols.
Research Applications and Future Directions
SS-31 continues to be investigated across a broad range of mitochondrial dysfunction models. Active areas of preclinical research include skeletal muscle atrophy, diabetic cardiomyopathy, ocular pathologies involving retinal mitochondrial stress, and age-related metabolic decline. The peptide’s mechanism of action, targeting a structural lipid rather than a specific protein, positions it as a tool for studying mitochondrial membrane biology across diverse tissue types.
For researchers studying mitochondrial biology, peptide pharmacology, or organelle-targeted therapeutics, SS-31 represents a well-characterized probe with a substantial published evidence base. Canadian researchers can access high-purity research peptides with independent third-party COA verification through domestic suppliers, ensuring both quality transparency and efficient same-day shipping within Canada.
Related research: Explore our deep-dives on BPC-157, MOTS-C mitochondrial signaling, and NAD+ cellular repair pathways for complementary perspectives on mitochondrial-targeted research compounds.
For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.
Maple Research Labs provides Canadian-manufactured research peptides with independent third-party COA verification by Janoshik Analytical. All products ship same-day from Canada.